Form D · Pharmaceuticals
Mebias Discovery, Inc.
Philadelphia, PA · CIK 0001782138
Offering snapshot reported Sep 23, 2022 · SEC filing
- Reported sold
- $631K Offering amount: $2.05M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 15, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 23, 2022 | Initial | $630,682 | No comparison | 2 | SEC filing |
| Jul 11, 2019 | Initial | $2,993,205 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-459737
A portion of the offering amount remaining to be sold is contemplated to be issued in exchange for services to be performed by a Company service provider pursuant to a service agreement
Source: Form D, filed Sep 23, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Shariff S. Bayoumy | Executive |
| Guanghui Hu | Director |
| Lawrence C. Kuo | Executive |
| Barbara Schilberg | Director |
| Michael Serrano Wu | Director |
| Brett A. Tounge | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3675 Market Street, Suite 200
Philadelphia, PA, 19104
Philadelphia, PA, 19104